A multi-source data fusion bronchoscope whole-process management system, method and chip

Abstract

This invention provides a multi-source data fusion-based bronchoscope end-to-end management system, method, and chip, belonging to the field of data management technology. Specifically, it includes: a clinical diagnosis and treatment module responsible for patient information association, bronchoscope usage record registration, and post-use status registration; a processing module responsible for receiving and confirming the entire bronchoscope processing record, automatically collecting cleaning parameters, and using the fluctuations in the bronchoscope's lifespan in different disease types to determine the remaining lifespan assessment method for the bronchoscope in the given disease type; a linkage module responsible for receiving microbial monitoring requests, reporting monitoring results, and automatically triggering early warning and recall processes; and a central monitoring module responsible for displaying the real-time status of all bronchoscopes, graphically displaying the complete bronchoscope flow path and all operation records, and generating various reports, thereby improving the reliability of bronchoscope lifespan management.

Description

Technical Field

[0001] This invention belongs to the field of data management technology, and in particular relates to a multi-source data fusion-based bronchoscope end-process management system, method and chip. Background Technology

[0002] As an important invasive diagnostic and treatment device, the bronchoscope is widely used in the diagnosis and treatment of respiratory diseases. Its management involves multiple independent departments, including clinical departments, central sterile supply departments (CSSD), and microbiology laboratories, resulting in complex business processes and extremely high safety requirements.

[0003] The existing fiberoptic bronchoscopy management system has the following main technical defects: The problem of data silos is serious: key data such as clinical usage records, CSSD cleaning, disinfection and sterilization parameters, and microbial culture results are stored in different business information systems (such as HIS, CSSD traceability system, LIS). There is a lack of effective data exchange and sharing mechanisms between systems, which leads to the artificial fragmentation of the entire life cycle information of medical devices from "use-cleaning-testing-reuse".

[0004] Insufficient traceability: When a suspected infection or device malfunction occurs, traditional systems often only provide records of partial steps, failing to quickly and accurately link to the complete historical treatment information of the same patient and the same device. Manually reviewing paper records or querying across systems is inefficient and prone to errors.

[0005] The use of bronchoscopes varies across different disease types, resulting in variations in their lifespan. Therefore, determining a strategy for assessing and analyzing the remaining lifespan based on these variations, and utilizing the highly efficient bronchoscope to identify and address potential risks associated with abnormal operation of disinfection devices, thereby ensuring the reliability and efficiency of the assessment and analysis of the remaining lifespan, has become a pressing technical challenge.

[0006] Specifically, this application provides a multi-source data fusion-based bronchoscope end-to-end management system, method, and chip. Summary of the Invention

[0007] To achieve the objectives of this invention, the following technical solution is adopted: Specifically, this application provides a multi-source data fusion-based bronchoscope end-to-end management system, which includes: The system includes a clinical diagnosis and treatment module, a processing module, a linkage module, and a central monitoring module. The clinical diagnosis and treatment module is responsible for linking patient information, registering the use records of the bronchoscope, and registering the status after use. The processing module is responsible for receiving and confirming the entire process record of the bronchoscope, automatically collecting cleaning parameters, and using the fluctuation of the bronchoscope's lifespan in different disease types to determine the assessment and analysis method for the remaining lifespan of the bronchoscope in the disease type. Based on the usage data of the bronchoscope for the target risk type and the assessment risk type of different disease types, the module determines the disinfection management strategy for the target risk type. Based on the assessment and analysis results of the remaining lifespan of different bronchoscopes and the assessment and analysis processing data, the module determines the updated management strategy for the assessment and analysis method of the remaining lifespan of the bronchoscope for the disease type. The linkage module is responsible for receiving microbial monitoring applications, reporting monitoring results, and automatically triggering early warning and recall processes. The central monitoring module is responsible for displaying the status of all bronchoscopes in real time, graphically displaying the complete flow path of the bronchoscopes and all operation records, and generating various reports.

[0008] Furthermore, the complete process record of the bronchoscope includes leak detection, cleaning, disinfection, drying, and storage of the bronchoscope.

[0009] Furthermore, the reports include workload, pass rate, early warning rate, and consumable usage.

[0010] Secondly, this application provides a multi-source data fusion-based method for managing the entire process of bronchoscope procedures, applied to the aforementioned multi-source data fusion-based bronchoscope process management system, specifically including: S1 uses data on the use of bronchoscopes to determine the fluctuation of the lifespan of bronchoscopes in different disease types. Based on the fluctuation, it determines the assessment and analysis method for the remaining lifespan of the bronchoscope in the disease type. Using the assessment and analysis method, it determines the assessment risk type for different disease types. Based on the data on the use of bronchoscopes of the target risk type and in combination with the assessment risk type for different disease types, it determines the disinfection management strategy for the target risk type. S2 uses the assessment and analysis results of the remaining lifespan of bronchoscopes of different target risk types in different disinfection cabinets to identify bronchoscopes whose remaining lifespan variation does not meet the requirements. Combined with the assessment and analysis results of the remaining lifespan of the bronchoscopes whose remaining lifespan variation does not meet the requirements in other disinfection cabinets, the target for assessment and analysis of the remaining lifespan of bronchoscopes is determined. S3 determines the updated management strategy for the assessment and analysis method of the remaining lifespan of the bronchoscope for the disease type based on the assessment and analysis results of the remaining lifespan when different bronchoscopes are used as assessment and analysis targets, as well as the assessment and analysis processing data.

[0011] The beneficial effects of this invention are as follows: By analyzing the fluctuations in the lifespan of bronchoscopes across different disease types, this study determines the assessment and analysis methods for the remaining lifespan of bronchoscopes in different disease types. Through analyzing historical usage data of bronchoscopes in various diseases (mainly the fluctuations in usage quantity and lifespan), and considering both high-risk scenarios with extremely unstable lifespan performance in specific diseases and the overall stability of all disease types, disease types are divided into different risk levels. Differentiated remaining lifespan assessment strategies (i.e., different baseline usage counts) are assigned to each level, ensuring the reliability and timeliness of the overall remaining lifespan assessment and analysis.

[0012] Based on the assessment and analysis results of the remaining lifespan of bronchoscopes whose remaining lifespan changes do not meet the requirements in other disinfection cabinets, the assessment and analysis targets for the remaining lifespan of bronchoscopes are determined. By utilizing high-frequency assessment data of bronchoscopes of the target risk type, disinfection cabinets with operational abnormalities are accurately identified. Then, based on the usage of non-target risk type bronchoscopes in these abnormal disinfection cabinets, it is determined whether they also have the risk of abnormal lifespan due to the disinfection environment. This determines whether additional and more frequent remaining lifespan assessments need to be initiated for the non-target risk bronchoscopes, thereby improving the comprehensiveness and reliability of the overall remaining lifespan assessment and analysis.

[0013] Furthermore, the usage data of the bronchoscope includes the number of times the bronchoscope is used in different disease types and its lifespan.

[0014] Furthermore, the fluctuation in the lifespan of the bronchoscope in different disease types is determined based on the lifespan range of the bronchoscope in each disease type.

[0015] Furthermore, the method for determining the remaining lifespan of the bronchoscope in the disease type is as follows: S11 determines the lifespan range of the bronchoscope in the disease type based on the fluctuation situation; S12 determines the lifespan matching coefficient of the service life range by the proportion of the number of bronchoscopes in different service life ranges. S13 is an assessment and analysis method for determining the remaining lifespan of the bronchoscope in the disease type based on the lifespan matching coefficient of different disease types in different lifespan ranges.

[0016] Furthermore, the method for determining the updated management strategy for assessing and analyzing the remaining lifespan of the bronchoscope for the aforementioned disease type is as follows: S41 uses the remaining life assessment results of different bronchoscopes as assessment and analysis targets to determine the proportion of bronchoscopes whose remaining life variation does not meet the requirements, and regards it as the abnormal variation proportion. S42 determines the number of evaluation and analysis processes for the bronchoscope as the evaluation and analysis target based on the evaluation and analysis data; S43 is an update management strategy for the assessment and analysis method that determines the remaining lifespan of the bronchoscope for the disease type based on the abnormal variation ratio and the number of assessment and analysis processes using different bronchoscopes as assessment and analysis targets.

[0017] Thirdly, this application provides a chip for the aforementioned multi-source data fusion-based bronchoscope end-to-end management system, characterized in that it specifically includes: The data acquisition interface is configured to acquire usage data of the bronchoscope, and the storage unit is configured to store preset threshold parameters and program instructions.

[0018] Other features and advantages will be set forth in the description which follows, and will be apparent in part from the description, or may be learned by practicing the invention. The objects and other advantages of the invention are realized and obtained through the structures particularly pointed out in the description and the drawings.

[0019] To make the above-mentioned objects, features and advantages of the present invention more apparent and understandable, preferred embodiments are described below in detail with reference to the accompanying drawings. Attached Figure Description

[0020] The above and other features and advantages of the present invention will become more apparent from a detailed description of exemplary embodiments thereof with reference to the accompanying drawings.

[0021] Figure 1 This is a framework diagram of a multi-source data fusion-based bronchoscopy end-to-end management system; Figure 2 This is a flowchart of a multi-source data fusion method for the entire process management of bronchoscopes; Figure 3 This is a flowchart of a method for determining the remaining lifespan of a bronchoscope in the aforementioned disease type. Detailed Implementation

[0022] Exemplary embodiments will now be described more fully with reference to the accompanying drawings. However, these exemplary embodiments can be implemented in many forms and should not be construed as limited to the embodiments set forth herein; rather, they are provided so that the invention will be thorough and complete, and the concept of the exemplary embodiments will be fully conveyed to those skilled in the art. The same reference numerals in the drawings denote the same or similar structures, and therefore their detailed description will be omitted.

[0023] The terms “a,” “one,” “the,” and “the” are used to indicate the existence of one or more elements / components / etc.; the terms “including” and “having” are used to indicate an open-ended meaning of inclusion and that other elements / components / etc. may exist in addition to the listed elements / components / etc.

[0024] Example 1 To solve the above problems, according to one aspect of the present invention, such as Figure 1 As shown, a multi-source data fusion-based end-to-end management system for bronchoscopes is provided, specifically including: The system includes a clinical diagnosis and treatment module, a processing module, a linkage module, and a central monitoring module. The clinical diagnosis and treatment module is responsible for linking patient information, registering the use records of the bronchoscope, and registering the status after use. The processing module is responsible for receiving and confirming the entire process record of the bronchoscope, automatically collecting cleaning parameters, and using the fluctuation of the bronchoscope's lifespan in different disease types to determine the assessment and analysis method for the remaining lifespan of the bronchoscope in the disease type. Based on the usage data of the bronchoscope for the target risk type and the assessment risk type of different disease types, the module determines the disinfection management strategy for the target risk type. Based on the assessment and analysis results of the remaining lifespan of different bronchoscopes and the assessment and analysis processing data, the module determines the updated management strategy for the assessment and analysis method of the remaining lifespan of the bronchoscope for the disease type. The linkage module is responsible for receiving microbial monitoring applications, reporting monitoring results, and automatically triggering early warning and recall processes. The central monitoring module is responsible for displaying the status of all bronchoscopes in real time, graphically displaying the complete flow path of the bronchoscopes and all operation records, and generating various reports.

[0025] Furthermore, the complete process record of the bronchoscope includes leak detection, cleaning, disinfection, drying, and storage of the bronchoscope.

[0026] Furthermore, the reports include workload, pass rate, early warning rate, and consumable usage.

[0027] Example 2 Secondly, such as Figure 2 As shown, this application provides a multi-source data fusion-based bronchoscope workflow management method, applied to the aforementioned multi-source data fusion-based bronchoscope workflow management system, specifically including: S1 uses data on the use of bronchoscopes to determine the fluctuation of the lifespan of bronchoscopes in different disease types. Based on the fluctuation, it determines the assessment and analysis method for the remaining lifespan of the bronchoscope in the disease type. Using the assessment and analysis method, it determines the assessment risk type for different disease types. Based on the data on the use of bronchoscopes of the target risk type and in combination with the assessment risk type for different disease types, it determines the disinfection management strategy for the target risk type. S2 uses the assessment and analysis results of the remaining lifespan of bronchoscopes of different target risk types in different disinfection cabinets to identify bronchoscopes whose remaining lifespan variation does not meet the requirements. Combined with the assessment and analysis results of the remaining lifespan of the bronchoscopes whose remaining lifespan variation does not meet the requirements in other disinfection cabinets, the target for assessment and analysis of the remaining lifespan of bronchoscopes is determined. S3 determines the updated management strategy for the assessment and analysis method of the remaining lifespan of the disease type based on the assessment and analysis results of different bronchoscopes and the assessment and analysis processing data.

[0028] Furthermore, the usage data of the bronchoscope includes the number of times the bronchoscope is used in different disease types and its lifespan.

[0029] Furthermore, the fluctuation in the lifespan of the bronchoscope in different disease types is determined based on the lifespan range of the bronchoscope in each disease type.

[0030] Specifically, such as Figure 3 As shown, the method for determining the remaining lifespan of the bronchoscope in the disease type is as follows: In this embodiment, a method for dynamically and accurately matching the remaining service life of bronchoscopes for different disease types with their actual usage is used.

[0031] Its core decision-making logic is a multi-level risk assessment and classification system. Instead of applying a uniform lifespan assessment standard to all bronchoscopes, it constructs a decision tree by analyzing historical usage data (primarily fluctuations in usage frequency and lifespan) across various diseases. This decision tree first identifies high-risk scenarios with highly unstable lifespan performance in specific diseases, then analyzes the overall stability of all disease types, and finally further refines the analysis for medium-risk scenarios. This classifies disease types into different risk levels and assigns differentiated remaining lifespan assessment strategies (i.e., different baseline usage counts) to each level. The core of this logic lies in achieving optimized management and risk control of valuable medical equipment resources through refined classification.

[0032] S11 determines the lifespan range of the bronchoscope in the disease type based on the fluctuation situation; Fluctuation: This refers to the dispersion or range of variation in the recorded lifespan (e.g., total number of uses) of a bronchoscope when used to diagnose or treat a specific disease. For example, for the disease "pneumonia," some bronchoscopes may be discarded after 50 uses, while others may be used 200 times. The breadth of this data distribution is the fluctuation. Large fluctuations mean unstable lifespan performance.

[0033] Lifespan Range: For quantitative analysis, the entire possible lifespan of the bronchoscope is divided into several continuous, non-overlapping intervals. For example, the lifespan can be divided into multiple intervals such as [0, 50 times], (50, 100 times], (100, 150 times], (150, 200 times], etc.

[0034] Directly using precise lifespan values ​​for analysis is easily affected by individual extreme data and makes it difficult to establish a unified measurement standard. By dividing the data into intervals, continuous data can be discretized, and bronchoscopes with similar lifespan performance can be grouped into the same category, thereby reducing data noise and more clearly observing the lifespan distribution pattern of bronchoscopes in specific diseases.

[0035] This is a fundamental step in data analysis, establishing a standardized "coordinate system" for locating and comparing the lifespan performance of bronchoscopy under different disease types. For example, we can say that "for 'pneumonia,' the lifespan of most bronchoscopy sessions falls within the range of (100, 150)", thus forming an intuitive understanding.

[0036] Suppose a hospital collected data on the use of bronchoscopes in the treatment of bacterial pneumonia. The hospital defined the lifespan range as follows: Range A (1-50 uses), Range B (51-100 uses), Range C (101-150 uses), and Range D (151-200 uses). Statistical analysis revealed that most bronchoscopes used for bacterial pneumonia fell within Range C (101-150 uses) at the time of their obsolescence, but some fell within Range B (51-100 uses), and a very small number fell within Range D. This establishes the fluctuation in the lifespan of bronchoscopes for this disease type, primarily concentrated in Range C, but also occurring within Range B.

[0037] S12 determines the lifespan matching coefficient of the service life range by the proportion of the number of bronchoscopes in different service life ranges. Lifespan matching coefficient: This is a quantitative indicator used to measure the degree of matching between a specific lifespan range and a particular disease type. It is typically calculated by dividing the number of bronchoscopes used within that range by the total number of bronchoscopes used for that disease type. A higher ratio indicates that the lifespan performance within that range is more representative of the typical situation under this disease, and the higher the matching coefficient.

[0038] Knowing only which interval a bronchoscope falls into is insufficient; it's also necessary to understand the "representativeness" of that interval. If an interval contains the vast majority of bronchoscopes (e.g., 90%), then the life expectancy characteristics of that interval are highly significant. If bronchoscopes are scattered across multiple intervals, it indicates that life expectancy under this disease is diverse, with no absolutely dominant interval. The life expectancy matching coefficient is precisely for quantifying this representativeness.

[0039] It transforms the quantitative information of the distribution into a standardized, comparable weighting coefficient. This allows us to quantitatively assess the essential difference between "10% of bronchoscopy in interval C" and "80% of bronchoscopy in interval C".

[0040] Continuing with the previous example, in the case of "bacterial pneumonia," a total of 100 bronchoscope lifetime data were recorded. Of these, 10 fell into interval B, 80 into interval C, and 10 into interval D. Therefore, the lifetime matching coefficient for interval B is 10 / 100 = 0.1, for interval C it is 0.8, and for interval D it is 0.1. This means that the lifetime characteristics of interval C (101-150 times) best represent the general situation under this disease.

[0041] S13 is an assessment and analysis method for determining the remaining lifespan of the bronchoscope in the disease type based on the lifespan matching coefficient of different disease types in different lifespan ranges.

[0042] Furthermore, based on the lifespan matching coefficients of different disease types within different lifespan ranges, an assessment and analysis method is used to determine the remaining lifespan of the bronchoscope in the respective disease type, specifically including: S131 Based on the maximum value of the life matching coefficient in different lifespan ranges, determine the lifespan fluctuation coefficient of the disease type, and determine whether the lifespan fluctuation coefficient of the disease type is greater than the preset fluctuation coefficient threshold. If yes, determine that the assessment and analysis method for the remaining lifespan of the bronchoscope in the disease type is to perform the assessment and analysis of the remaining lifespan according to the baseline number of uses. If no, proceed to step S132. Life expectancy fluctuation coefficient: This is an indicator used to quantify the degree of instability in life expectancy within a single disease type. It is defined based on the highest life expectancy matching coefficient for that disease. For example, it can be defined as 1 - the maximum life expectancy matching coefficient. The higher the maximum matching coefficient (e.g., 0.9), the more concentrated the bronchoscopy is within a certain range, the more stable the life expectancy is, and the smaller the fluctuation coefficient (0.1); conversely, if the maximum matching coefficient is only 0.4, it indicates a dispersed distribution, unstable life expectancy, and a larger fluctuation coefficient (0.6).

[0043] Baseline number of uses: This is a conservative assessment method. For disease types deemed to have highly variable life expectancy (high risk), a relatively low number of safe uses will be used as a baseline for assessing remaining life expectancy via bronchoscopy. This is done to ensure medical safety to the greatest extent possible.

[0044] Preset volatility coefficient threshold: This is a pre-set value used to determine whether the "lifetime volatility coefficient" is high enough to require the activation of the highest level of risk management.

[0045] This is the first line of defense in risk control. Its core principle is "focusing on the big picture and letting go of the small details," prioritizing the identification and handling of the highest-risk scenarios. For diseases with highly unstable lifespans (for example, some lenses break after only a few uses, while others can last a long time), the most conservative assessment strategy must be adopted, with safety as the primary objective.

[0046] For procedures like "foreign body removal," the wear and tear on bronchoscopes varies greatly due to the significant differences in the type and location of the foreign body and the complexity of the procedure. Statistical analysis shows a very uniform distribution across different lifespan intervals, with a maximum matching coefficient of only 0.3, and a calculated lifespan fluctuation coefficient of 1-0.3=0.7. If the preset fluctuation coefficient threshold is set to 0.6, 0.7 > 0.6, indicating a high risk. Therefore, for bronchoscopes used in "foreign body removal," the remaining lifespan assessment will use a "baseline number of uses" (e.g., conservatively assessing remaining lifespan every 10 uses) rather than a more optimistic assessment method.

[0047] S132 determines the lifespan fluctuation value of the bronchoscope based on the average lifespan fluctuation coefficient of different disease types, and determines whether the lifespan fluctuation value of the bronchoscope is greater than the preset fluctuation threshold. If yes, proceed to step S133. If no, determine that the assessment and analysis method for the remaining lifespan of the bronchoscope in the disease type is to conduct the assessment and analysis of the remaining lifespan according to the preset number of uses, wherein the preset number of uses is greater than the baseline number of uses. Life expectancy fluctuation value: This is a higher-level, global indicator. It is the statistical average of life expectancy fluctuation coefficients for all (or most) disease types, reflecting the overall stability of life expectancy performance across different diseases when using bronchoscopy in a hospital or department.

[0048] Preset volatility threshold: This is another preset value used to determine whether the "lifespan volatility value" of the entire system is too high. It differs from the "preset volatility coefficient threshold" in S131; the former is used to screen for individual high-risk diseases, while the latter is used to assess the overall risk level.

[0049] Preset number of uses: This is a standard assessment method. It refers to using a more optimistic and universally applicable standard number of uses than the "baseline number of uses" to assess remaining life for bronchoscopy when the overall risk is controllable and the current disease itself does not belong to the high-risk category.

[0050] This is the second line of defense in risk control, used to assess the systemic risk level. If the overall lifespan fluctuation value is not high, it indicates that the lifespan of bronchoscopy patients is relatively stable across most disease types, and a more universal standard (preset number of uses) can be confidently used for evaluation. If the overall fluctuation value is high, it indicates widespread uncertainty in the system, requiring a more refined third-step analysis.

[0051] This step serves as a bridge between the preceding and following steps. It uses global statistical data (lifespan fluctuation values) to determine whether a more complex individualized analysis needs to be initiated (S133). If the global data is stable, management is simplified, and standard methods are directly adopted; if the global data is unstable, it indicates that further investigation is needed.

[0052] The hospital compiled statistics on the types of diseases requiring bronchoscopy, including pneumonia, lung cancer, and foreign body removal procedures. After calculating the lifespan fluctuation coefficient for each disease, the average value was found to be 0.3. If the preset fluctuation threshold is set to 0.4, 0.3 < 0.4, indicating that the overall bronchoscopy lifespan performance in the hospital is stable. Therefore, for diseases not classified as high-risk in S131 (such as "pneumonia"), the remaining lifespan assessment directly adopts the "preset number of uses" (e.g., assessing remaining lifespan every 20 uses), which is more lenient than the "baseline number of uses" (10 uses).

[0053] S133 determines the lifespan ranges with lifespan matching coefficients greater than a preset coefficient threshold based on lifespan matching coefficients in different lifespan ranges, and uses these as screening lifespan ranges. It then determines whether the number of screening lifespan ranges is greater than a preset screening range number threshold. If so, it determines that the assessment and analysis method for the remaining lifespan of the bronchoscope in the disease type is to perform the remaining lifespan assessment and analysis processing according to the target number of uses. If not, it determines that the assessment and analysis method for the remaining lifespan of the bronchoscope in the disease type is to perform the remaining lifespan assessment and analysis processing according to a preset number of uses.

[0054] Preset coefficient threshold: A pre-defined lifespan matching coefficient value used to determine whether a lifespan range qualifies as a "major" or "significant" manifestation range for this disease type. For example, it can be set to 0.2, meaning only ranges with a matching coefficient greater than 0.2 are considered significant.

[0055] Lifetime range selection: After filtering by preset coefficient thresholds, the remaining ranges have higher lifetime matching coefficients.

[0056] Preset threshold for the number of screening intervals: A pre-defined value used to determine whether the number of "screened lifespan intervals" is too high or too low. For example, it can be set to 2. If more than 2 intervals are selected, it indicates that the lifespan pattern of this disease type is diverse, and there is no absolute mainstream.

[0057] Target usage count: This is an assessment method that falls between conservative and standard approaches. It is used for disease types with overall system instability (high life expectancy fluctuations) but relatively concentrated life expectancy patterns. The number of assessments (target usage count) is less than the standard approach's "preset usage count" but greater than the conservative approach's "baseline usage count".

[0058] This is a refined classification for situations of "overall system instability." It further analyzes the lifespan distribution pattern for each specific disease type. If the lifespan of a disease type is concentrated in a few intervals (few selection intervals), it indicates that its internal pattern is clear, and standard methods such as "preset usage counts" can continue to be used. However, if the lifespan of a disease type is dispersed across multiple significant intervals (many selection intervals), it indicates that there is also considerable uncertainty within it, and the evaluation criteria need to be tightened appropriately, adopting a more conservative "target usage count" than the standard method.

[0059] This is the most refined layer in the decision-making logic, avoiding a blanket conservative approach to all diseases when the system as a whole is unstable. By analyzing the patterns of disease types themselves, it distinguishes between "systemic risk" and "individual patterns," achieving more precise classification and management that both controls risk and optimizes equipment utilization as much as possible.

[0060] A specific example: Suppose the lifespan fluctuation value calculated in S132 is 0.5, which is greater than the preset fluctuation threshold of 0.4, proceeding to S133. Now analyze the disease type of "bronchial biopsy". Its matching coefficients in different lifespan intervals are: interval A 0.1, interval B 0.3, interval C 0.4, interval D 0.2. Set the preset coefficient threshold to 0.25. Then, the intervals with matching coefficients greater than 0.25 are B (0.3) and C (0.4), but there are actually only two intervals, B and C, totaling 2. If the preset screening interval number threshold is set to 1, then 2>1, meaning that there are multiple significant lifespan patterns in this disease type, with high uncertainty. Therefore, for the fiberoptic bronchoscope in "bronchial biopsy", its remaining lifespan assessment will adopt the "target number of uses" (e.g., assessing remaining lifespan every 15 uses), which is relatively lenient.

[0061] Furthermore, the number of times the remaining life expectancy assessment analysis is performed is determined for the disease type assessment risk type, wherein the assessment risk type includes target risk type, general risk type and normal risk type, wherein the target risk type is the baseline number of abnormal uses, the general risk type is the preset number of uses, and the normal risk type is the target number of uses.

[0062] Specifically, the method for determining the disinfection management strategy for the target risk type of disease is as follows: Differentiated bronchoscope disinfection management strategies are developed for different risk levels of disease types. Based on the implementation of the "one bronchoscope, one cabinet" binding model, the distribution of high-risk (target risk type) bronchoscopes in different disinfection cabinets is optimized to achieve reliable monitoring of the operating status of all disinfection cabinets. At the same time, based on the total number of high-risk bronchoscopes, the range of disease types that may be affected by the failure of a single disinfection cabinet is dynamically controlled. Ultimately, this provides a precise environmental correction basis for assessing the remaining lifespan of bronchoscopes of all risk types.

[0063] The core variables in decision-making are the number of target risk diseases and the total number of bronchoscopes associated with those diseases. When the number of target risk diseases is small, to achieve monitoring coverage of all sterilizers, the limited number of high-risk bronchoscopes needs to be distributed across all sterilizers. In this case, due to the limited total number of bronchoscopes, the number allocated to each sterilizer may be small, therefore, there is no strict limit on the number of disease types covered by each sterilizer. When the number of target risk diseases is large, the total number of bronchoscopes associated with these diseases is usually also large, naturally covering most or even all sterilizers. At this point, the management focus shifts from "achieving coverage" to "controlling risk," meaning it is necessary to strictly control the number of disease types involved in each sterilizer to avoid a situation where too many types of diseases simultaneously malfunction due to a single sterilizer failure, leading to poor reliability.

[0064] S21 uses data on the use of bronchoscopes for the target risk type to determine the number of bronchoscopes used for the target risk type. It is understandable that if the number of disease types in the target risk type is less than the preset disease type number threshold, then it is necessary to rely on the abnormal fluctuations in the remaining lifespan of the disease types detected at high frequency to determine whether the disinfection device has a serious impact on the remaining lifespan. Therefore, on this basis, it is necessary to determine the disinfection management strategy for the disease types in the target risk type as follows: each bronchoscope is disinfected only using a pre-fixed disinfection cabinet, and the goal is to maximize the number of disinfection cabinets with the same number of bronchoscopes in different disinfection cabinets. Additionally, it can be understood that if the number of disease types of the target risk type is not less than a preset disease type number threshold, then proceed to step S22.

[0065] Number of disease types in the target risk category: This refers to the number of specific disease types classified into the target risk level. For example, if both "foreign body removal" and "stenosis dilation" are target risks, then the number is 2.

[0066] Number of devices in use (specifically, the physical number of bronchoscopes): This refers to the total number of bronchoscopes in use for all target risk disease types during the current management period. This number determines the total "probe" resources available for deploying monitoring sites.

[0067] Preset disease type threshold: A pre-defined integer limit used to determine the number of target risk disease types. When the actual number is lower than this threshold, it is considered that there are fewer high-risk disease types, and the total number of bronchoscopes possessed is usually limited, making it difficult to naturally cover all sterilization cabinets.

[0068] The goal is to maximize the number of disinfection cabinets with a consistent number of bronchoscopes in different disinfection cabinets: This means that when allocating bronchoscopes to various disinfection cabinets, the priority is to allocate as many disinfection cabinets as possible with bronchoscopes, and to make the number of bronchoscopes in each allocated disinfection cabinet as even as possible, in order to maximize monitoring coverage.

[0069] This step is the first level of triage, based on an initial assessment of the absolute number of high-risk disease types. When there are few high-risk disease types, the total number of bronchoscopes available is usually also limited. If these limited bronchoscopes are concentrated in a few sterilizers, a large number of sterilizers will be unmonitored. To achieve reliable monitoring of all sterilizers, the limited number of high-risk bronchoscopes must be distributed as "monitoring probes" to each sterilizer. Therefore, the strategy is to enforce a "one bronchoscope per sterilizer" system, allocating resources to cover as many sterilizers as possible and balance the load, even if this results in some sterilizers containing a mix of disease types, because the primary goal at this point is comprehensive coverage.

[0070] This reflects the principle of "monitoring coverage taking precedence over risk diversification." When monitoring resources are scarce, priority is given to ensuring that every piece of disinfection equipment is included in the monitoring scope, laying the foundation for a comprehensive understanding of the impact of the disinfection process on the equipment's lifespan.

[0071] A hospital's endoscopy center has 8 sterilization cabinets. Preliminary assessment identified only two procedures—foreign body removal and stenosis dilation—as target risk types, with 5 and 3 bronchoscopes respectively, for a total of 8 in use. If the preset threshold for the number of disease types is set to 3, then 2 < 3, satisfying the condition. Therefore, the system will enforce a "one bronchoscope, one cabinet" binding for these 8 bronchoscopes, allocating them with the goal of "covering the most sterilization cabinets." Ideally, the system will distribute them across all 8 sterilization cabinets (1 bronchoscope per cabinet), ensuring that each cabinet has at least one target risk bronchoscope, thus enabling continuous monitoring of all 8 cabinets. While each cabinet is bound to only one disease type, if the number of bronchoscopes exceeds the number of cabinets, a situation may arise where one cabinet is bound to multiple disease types. However, to cover all cabinets, this mixing is permitted.

[0072] S22 determines the number of disease types in different risk assessment types based on the risk assessment types of different disease types; In the above steps, the number of disease types in different risk assessment types is obtained. Based on the number of disease types in different risk assessment types, the monitoring and analysis demand factor of the disinfection device is determined. It is determined whether the monitoring and analysis demand factor of the disinfection device is greater than the preset demand factor threshold. If yes, proceed to step S23. If no, the disinfection management strategy for the disease types of the target risk type is determined to be based on the number of disease types corresponding to the bronchoscopes disinfected in different disinfection cabinets being within the target number range, and the bronchoscopes are allocated and processed accordingly.

[0073] Risk type assessment: This includes target risk type, general risk type, and normal risk type, representing the risk level of different diseases on the lifespan of bronchoscopy.

[0074] The monitoring and analysis demand factor for disinfection devices is a comprehensive quantitative indicator used to assess the urgency of detailed monitoring and analysis of the entire disinfection system. It is typically constructed based on the number of diseases of different risk types, and can be defined as the ratio of (number of general risk disease types + number of normal risk disease types) to the number of target risk disease types. A larger factor indicates a greater variety of non-high-risk diseases, a higher load and complexity on the entire disinfection system, and a stronger demand for monitoring.

[0075] Preset demand factor threshold: A pre-set value used to determine whether the "monitoring and analysis demand factor" is high enough to require initiating a more complex analysis process (S23) to determine an appropriate risk diversification strategy.

[0076] Target quantity range: A predefined integer range (e.g., [1,2]) representing the upper limit of the number of disease types from which bronchoscopes can be simultaneously sterilized in each sterilizer. This mode aims to mitigate risk by controlling the number of disease types involved in each sterilizer.

[0077] When there are many high-risk disease types (not less than the threshold), the total number of bronchoscopes used is usually also large, and these bronchoscopes can naturally cover most or even all of the sterilizers. Therefore, the goal of "full coverage" has been automatically achieved, and the management priority shifts to "risk diversification." At this point, it is necessary to assess the "pressure" from other risk types of diseases in the system. If there are relatively few non-high-risk disease types (low demand factor), it indicates that the overall complexity of the system is not high, and the target quantity range can be directly used to control the number of disease types in each sterilizer to achieve risk diversification. If the demand factor is high, the system complexity and mixed pressure are high, requiring more in-depth decision-making to determine the optimal degree of diversification.

[0078] This step enables the management objective to shift from "comprehensive monitoring" to "risk diversification," allowing the strategy to adapt to the new situation where there is an increase in the types of high-risk diseases and monitoring resources are no longer scarce.

[0079] Assuming the target risk disease types increase to 4, which is not less than the preset disease type threshold of 3, proceed to S22. There are 40 bronchoscopes for these 4 diseases, a sufficient quantity. Statistics show: 4 target risks, 3 general risks, and 1 normal risk. If the demand factor is defined as (3+1) / 4 = 1.0, and the preset demand factor threshold is 0.8, then 1.0 > 0.8, proceed to S23. If the preset demand factor threshold is 1.2, then 1.0 < 1.2. In this case, the strategy is determined as follows: allocation is based on the number of target risk disease types processed in each sterilizer falling within the target quantity range [1,2]. For example, the 40 bronchoscopes can be allocated to 8 sterilizers, but it is ensured that the bronchoscopes in any sterilizer originate from no more than 2 target risk disease types, reducing the risk impact.

[0080] S23 determines the disinfection management strategy for the disease type of the target risk type based on the number of bronchoscopes used in the target risk type and the number of disease types in different assessed risk types.

[0081] Furthermore, determine whether the proportion of the disease type of the target risk type in all the disease types used by bronchoscopes is less than a preset proportion threshold. If so, each bronchoscope of the target risk type is disinfected only using a pre-fixed disinfection cabinet, and the goal is to maximize the number of disinfection cabinets with the same number of bronchoscopes in different disinfection cabinets. If not, proceed to the next step. Based on the number of bronchoscopes used for different target risk types, the average number of bronchoscopes used for each target risk type is determined. It is then determined whether the average number of bronchoscopes used for each target risk type is less than a preset usage threshold. If so, the disinfection management strategy for the bronchoscopes of the target risk type is determined to be based on the number of disease types corresponding to the bronchoscopes disinfected in different disinfection cabinets being within a target number range, and the bronchoscopes are then allocated accordingly. If not, the disinfection management strategy for the bronchoscopes of the target risk type is determined to be based on the number of disease types corresponding to the bronchoscopes disinfected in different disinfection cabinets being within a specified number range, and the bronchoscopes are then allocated accordingly.

[0082] Number of devices used (physical units): This refers to the number of bronchoscopes available for each target risk disease type. This data reflects the "weight" of each disease in the resource usage of the sterilizer.

[0083] Preset Proportion Threshold: A pre-defined proportion value used to determine the "significance" of the target risk disease among all disease types. If the proportion of the target risk disease is very low, it means that they are still a minority in the system, and the total number of bronchoscopes they possess may not be dominant. In order to achieve full coverage of the disinfection cabinets, it is still necessary to prioritize distributing them among the various disinfection cabinets.

[0084] Number of bronchoscopes used (referring to the average number of bronchoscopes per disease type): This is calculated by dividing the total number of bronchoscopes for all target risk disease types by the number of target risk disease types. It reflects the average number of "monitoring probes" available for each target risk disease. The higher this average, the more bronchoscopes are available for each disease. These bronchoscopes are naturally distributed among the sterilization cabinets. Even if a cabinet contains multiple diseases, it ensures that each disease has enough bronchoscopes distributed in other cabinets, thereby reducing the devastating impact of a single cabinet failure on disease monitoring.

[0085] Preset usage threshold: A pre-set value used to determine whether the average number of bronchoscopes used for the target risk disease is too high or too low.

[0086] Specify quantity range: Another predefined integer range (e.g., [3,4]), with an upper limit greater than the upper limit of the "target quantity range," indicating that a single sterilizer is allowed to handle bronchoscopy for a wider variety of diseases simultaneously. This is a more lenient hybrid strategy adopted to simplify management when the average number of endoscopes is high and the risk tolerance is strong.

[0087] This is a further refined analysis of the "high-demand factor" situation, introducing two key dimensions: the relative size of the target risk disease and the average amount of monitoring resources available for it.

[0088] Relative Scale: If the absolute number of target risk diseases is large, but their proportion among all diseases is small, they remain a scarce resource. To avoid leaving monitoring blind spots, they should still be distributed in a more dispersed manner (returning to the logic of S21).

[0089] Average Monitoring Resource Quantity: If the average number of bronchoscopes for a target risk disease is high, it means that there are enough bronchoscopes distributed across various sterilization cabinets for each disease. Therefore, different target risk types involve a large number of sterilization cabinets. In this case, to further reduce risk, a smaller preset quantity range is used to reduce the impact. Conversely, if the average number of bronchoscopes is low, the number of sterilization cabinets involved for each target risk disease is large. The number of disease types (target quantity range) in each sterilization cabinet can be more leniently controlled to prevent the complete loss of monitoring data for a single disease due to a single malfunction.

[0090] This is the most refined layer in the decision-making logic. By assessing the "scale" and "resource abundance" of the target risk disease itself, and on the premise that "comprehensive monitoring" has been basically achieved, the strictness of "risk diversification" is further optimized, thus achieving the optimal match between resource sufficiency and management refinement.

[0091] Continuing with the previous example, the demand factor 1.0 > 0.8, proceeding to S23. There are a total of 8 disease types (4 target risk diseases + 3 general diseases + 1 normal disease), and the proportion of target risk diseases = 4 / 8 = 0.5. Assuming a preset proportion threshold of 0.3, 0.5 > 0.3, which does not meet the "less than" condition. Therefore, a comprehensive coverage strategy is not adopted, and we proceed to the next step.

[0092] Determining the average number of bronchoscopes used (average number of bronchoscopes per target risk disease): There are a total of 40 bronchoscopes for the four target risk diseases, with an average of 10 bronchoscopes per disease. Assuming a preset usage threshold of 8 bronchoscopes, 10 > 8, which does not meet the "less than" condition. Therefore, the disinfection management strategy is determined as follows: Distribution is based on the number of bronchoscopes corresponding to the disease types being disinfected in different disinfection cabinets falling within a specified range [1,2]. That is, each disinfection cabinet can be equipped with a maximum of 2 bronchoscopes for different target risk diseases. Since there are an average of 10 bronchoscopes per disease, this is sufficient to distribute them across multiple disinfection cabinets. An malfunction in any cabinet will affect the entire cabinet; therefore, distribution can reduce the risk of a high-risk situation arising from an malfunction in any single cabinet.

[0093] One bronchoscope per cabinet: This means that after the aforementioned decision-making process, regardless of the final allocation rule, each target risk bronchoscope is fixedly assigned to a specific disinfection cabinet, forming a "blankoscope-cabinet" binding relationship.

[0094] Furthermore, the maximum value of the endpoints of the specified quantity range is greater than the maximum value of the endpoints of the target quantity range.

[0095] Furthermore, for bronchoscopes whose remaining lifespan does not meet the requirements, the determination is based on the trend of remaining lifespan variation, specifically including: The change in remaining life compared to the previous life assessment process is used as the change in the current life assessment process. If the variation in remaining lifespan of the bronchoscope gradually increases in different lifespan assessment processes, and the number of lifespan assessment processes that exceed the average variation in remaining lifespan of the bronchoscopes for the disease type is above the preset number of assessment processes, then the bronchoscope is determined to be a bronchoscope whose remaining lifespan variation does not meet the requirements.

[0096] Specifically, the method for determining the assessment and analysis target of the remaining lifespan in the bronchoscope is as follows: By utilizing high-frequency assessment data from target-risk type bronchoscopes, disinfection cabinets with operational abnormalities can be accurately identified. Then, based on the usage of non-target-risk type bronchoscopes in these abnormal disinfection cabinets, it can be determined whether they also have an abnormal lifespan risk due to the disinfection environment, thereby deciding whether additional and more frequent remaining lifespan assessments need to be initiated for the non-target-risk bronchoscope.

[0097] Its core decision-making logic is a two-stage progressive monitoring and feedback optimization logic. The first stage (S31-S33) uses the target risk bronchoscope as a "biosensor" to identify disinfection cabinets that may have operational malfunctions by analyzing abnormal changes in their lifespan. Then, it traces the usage history of non-target risk bronchoscopes in these high-risk disinfection cabinets and combines it with their performance in other normal disinfection cabinets to determine whether the non-target risk bronchoscope has also shown disinfection cabinet-related anomalies, thereby deciding whether to list it as a "remaining life assessment analysis target" that requires key attention and initiate more frequent assessments.

[0098] S31 identifies bronchoscopes whose remaining lifespan variation does not meet the requirements among those bronchoscopes used only in the disinfection cabinet as abnormal bronchoscopes, and determines the proportion of abnormal bronchoscopes in the disinfection cabinet based on the proportion of abnormal bronchoscopes among those bronchoscopes used only in the disinfection cabinet. Using only the bronchoscope in the disinfection cabinet: This refers to a target risk type bronchoscope that is permanently attached to the disinfection cabinet for all disinfection operations under the "one bronchoscope, one cabinet" management model. These are dedicated "sensors" for monitoring the operating condition of the disinfection cabinet.

[0099] Abnormally variable bronchoscope: Target risk bronchoscope that meets the standard of "gradually increasing variation in remaining lifespan in multiple consecutive assessments".

[0100] Abnormal bronchoscope ratio in a disinfection cabinet: For a given disinfection cabinet, the proportion of all target risk bronchoscopes identified as "abnormal bronchoscopes".

[0101] This step utilizes the purest data source (target risk mirrors for each disinfection cabinet) to assess the health status of the disinfection cabinets. Changes in the lifespan of these mirrors directly reflect the operating conditions of the disinfection cabinets they are attached to. Calculating the proportion of abnormal bronchoscopy in each disinfection cabinet is equivalent to assigning a "risk score" to each cabinet; the higher the score, the greater the likelihood of the cabinet malfunctioning.

[0102] A specific example: Disinfection cabinet No. 1 is equipped with 10 target risk bronchoscopes. After continuous monitoring, 2 of them were identified as having abnormal changes. Therefore, the proportion of abnormal bronchoscopes in this disinfection cabinet is 2 / 10 = 20%. This 20% means that 20% of the "sensors" in cabinet No. 1 reported abnormalities, indicating a potential operational risk.

[0103] S32 designates the bronchoscope whose disease type matches that of the abnormal bronchoscope as the associated bronchoscope, and determines the abnormal bronchoscope data among the associated bronchoscopes based on the assessment and analysis results of the remaining lifespan of the associated bronchoscopes in other sterilization cabinets. Associated bronchoscope: A bronchoscope belonging to the same disease type as a target risk bronchoscope that was identified as having "abnormal changes," but which was sterilized using a different sterilizer. This is a control group.

[0104] Data on abnormal bronchoscopes in the associated bronchoscope group: This refers to the number of bronchoscopes in the control group that were also identified as having abnormal bronchoscopes. This data is used to determine whether the abnormality is widespread in bronchoscopes of this disease type, or whether it is only an individual problem in a specific sterilizer.

[0105] This step is crucial for attribution analysis. When a target risk mirror in cabinet 1 shows an abnormality, we need to know if this is a "common problem" for this type of issue. If other mirrors with the same issue are also generally abnormal in other cabinets, the problem may stem from the operational difficulty of the issue itself or inherent wear and tear on the equipment. If mirrors with the same issue in other cabinets are functioning normally, then the abnormality of this mirror in cabinet 1 strongly points to a problem with cabinet 1 itself.

[0106] By introducing a horizontal comparison across disinfection cabinets, the confusing factor of "the characteristics of the disease itself" is effectively eliminated, making the subsequent assessment of the risk of disinfection cabinets more accurate.

[0107] A bronchoscope, M, exhibiting abnormal behavior, was found in cabinet 1, classifying it as disease B. The system searched for all 15 bronchoscopes with disease B in other sterilization cabinets (cabinets 2, 3, and 4). Analysis revealed that only one of these 15 related bronchoscopes was also identified as abnormal in its own cabinet. This low percentage (1 / 15) strongly suggests that disease B itself is not the primary cause of M's abnormality; the problem likely lies within cabinet 1 itself.

[0108] S33 determines the associated disinfection cabinet of the bronchoscope based on the proportion of times the bronchoscope is used in different disinfection cabinets, and determines whether the bronchoscope belongs to the assessment and analysis target of the remaining life based on the proportion of abnormal bronchoscopes in different associated disinfection cabinets and the data of abnormal bronchoscopes in the associated bronchoscopes of different abnormal bronchoscopes.

[0109] It is understood that the associated disinfection cabinet is a disinfection cabinet whose usage rate is higher than a preset percentage.

[0110] Specifically, if the number of times the bronchoscope is used is less than a preset threshold, then the bronchoscope is determined not to be a target for the remaining lifespan assessment analysis.

[0111] Additionally, it is understood that if the number of times the bronchoscope is used is not less than a preset threshold, the following content is also included: Case 1: If the proportion of abnormal bronchoscopes in the associated disinfection cabinet of the bronchoscope is less than the preset bronchoscope proportion threshold, then the bronchoscope is determined not to be a target for the remaining life assessment analysis. Case 2: If the proportion of abnormal bronchoscopes in the associated disinfection cabinet of the bronchoscope is not less than the preset bronchoscope proportion threshold, and if the average proportion of abnormal bronchoscopes in the associated disinfection cabinet of the bronchoscope is greater than the preset abnormal proportion threshold, then the bronchoscope is determined to be a target for assessment and analysis of remaining lifespan. Scenario 3: If the average proportion of abnormal bronchoscopes in the associated disinfection cabinets of the bronchoscope is not greater than a preset abnormal proportion threshold, the abnormal correlation coefficient between the abnormal bronchoscope and the associated disinfection cabinet is determined based on the proportion of abnormal bronchoscopes in the associated bronchoscopes of the abnormal bronchoscopes. Based on the abnormal correlation coefficients between different abnormal bronchoscopes and the associated disinfection cabinets and the proportion of abnormal bronchoscopes in the associated disinfection cabinets, the comprehensive abnormal value of the associated disinfection cabinet is determined. It is then determined whether there is an associated disinfection cabinet with a comprehensive abnormal value greater than a preset abnormal threshold. If so, the bronchoscope is determined to be a target for the remaining life assessment analysis; otherwise, the bronchoscope is determined not to be a target for the remaining life assessment analysis.

[0112] It is understood that the abnormal correlation coefficient is the difference between 1 and the proportion of abnormal bronchoscopes in the associated bronchoscopes of the abnormal bronchoscope. The larger the abnormal correlation coefficient, the more likely the abnormal bronchoscope is to have an abnormal change in its remaining lifespan due to the influence of its corresponding associated sterilizer, while other bronchoscopes of the same disease type do not have abnormal changes. Therefore, the abnormal correlation coefficient is larger in this case.

[0113] Specifically, the overall abnormal value of the associated disinfection cabinet is determined based on the average of the abnormal correlation coefficient between different abnormal bronchoscopes and the associated disinfection cabinet and the proportion of abnormal bronchoscopes in the associated disinfection cabinet. The larger the abnormal correlation coefficient between different abnormal bronchoscopes and the associated disinfection cabinet, and the larger the proportion of abnormal bronchoscopes in the associated disinfection cabinet, the larger the overall abnormal value of the associated disinfection cabinet, and the higher the probability of abnormal temperature control or heating during the disinfection process.

[0114] Associated disinfection cabinet: For a non-target risk bronchoscope to be evaluated, the disinfection cabinet whose usage rate in its history reaches or exceeds the "preset usage rate" (e.g., 30%).

[0115] The target of the remaining life assessment analysis is: non-target risk bronchoscopy that, after this round of judgment, is considered to be highly likely to have an abnormal lifespan due to disinfection in an abnormal disinfection cabinet, and therefore requires more frequent remaining life assessment.

[0116] Preset bronchoscope ratio threshold: A low threshold used to determine whether the abnormal ratio of a single associated disinfection cabinet is "negligible". If the abnormal ratio of all associated cabinets is below this value, it indicates that the disinfection environment in which the bronchoscope is located is generally healthy, and no additional assessment is required.

[0117] Preset abnormality threshold: A relatively high threshold used to determine whether the average abnormality rate of associated disinfection cabinets is high enough to warrant a direct "crime".

[0118] Anomaly Correlation Coefficient: A quantitative indicator used to measure the strength of the correlation between the anomaly of a specific "variable abnormal bronchoscope" (target risk bronchoscope) and the sterilizer it is located in. The formula is 1 - (the proportion of variable abnormal bronchoscopes among the associated bronchoscopes of this disease type). The higher this coefficient, the more attributable the problem of the abnormal bronchoscope is to its associated sterilizer.

[0119] Overall Outlier: A comprehensive indicator used to assess the overall suspicion level of an associated disinfection cabinet. It takes into account both the proportion of abnormal bronchoscopy points within the cabinet itself and the anomalous correlation coefficients of all "variable abnormal bronchoscopy points" associated with that cabinet (to what extent these anomalies can be attributed to the cabinet). The higher the overall outlier, the greater the probability that the cabinet is faulty.

[0120] Preset anomaly threshold: Used to determine whether the overall anomaly value is high enough to confirm that the disinfection cabinet has a serious problem.

[0121] This is the core step in applying the monitoring results of targeted risk scopes to the assessment of non-target risk scopes. For a non-target risk scope N disinfected in cabinet 1 (e.g., with a usage rate of more than 0.5), we determine whether it is "affected" using the following logic: Data volume filtering: If the number of times it is used is too few, it will not be analyzed, as it is unlikely that there will be any abnormalities in its remaining lifespan.

[0122] Environmental filtration (Case 1): If cabinet 1 itself is "clean" (abnormal ratio is lower than the preset bronchoscope ratio threshold), then the lifespan of N should not be affected and is not listed as a target.

[0123] Direct conviction (situation 2): If the average abnormality rate of container 1 is already very high (above the preset abnormality rate threshold), it indicates that the environmental problem is serious and N is likely to be affected by it, and it will be directly listed as a target.

[0124] Detailed Attribution (Case 3): This is the most crucial part. When the anomaly rate of Cabinet 1 is moderate, we cannot draw simple conclusions. At this point, we utilize the "anomaly correlation coefficients" calculated previously in S32, which are related to each anomalous target risk mirror on Cabinet 1. If the average of these coefficients (overall anomaly value) is high, it indicates that the anomaly of the abnormal mirrors on Cabinet 1 is highly attributable to the cabinet itself. Therefore, even if the anomaly rate of Cabinet 1 is not extremely high, it is still a definite "problem cabinet," and the non-target risk mirror N disinfected on it should also be listed as a target.

[0125] This step successfully utilizes the target risk mirror as a highly sensitive "probe" to accurately quantify the risk status of the disinfection cabinet through complex attribution analysis. Based on this, it determines whether to initiate stricter monitoring of non-target risk mirrors sharing the same disinfection cabinet, thus achieving accurate risk transmission and on-demand allocation of assessment resources.

[0126] There is a non-target risk bronchoscope N (used for general risk type disease A), which was disinfected in disinfection cabinet 1 (95% usage rate), with a total of 50 uses (>threshold). Data from cabinet 1: The proportion of abnormal bronchoscopes is 20%, and the abnormal target risk bronchoscopes attached to it are M (disease B), X (disease E), and Y (disease F).

[0127] Case 1: If the abnormality rate of cabinet No. 1 is 2%, which is less than the preset bronchoscope ratio threshold of 5%, then N is not a target for evaluation and analysis.

[0128] Scenario 2: If the abnormality rate of cabinet No. 1 is 30%, which is greater than the preset abnormality rate threshold of 25%, then N belongs to the evaluation and analysis target.

[0129] Scenario 3: If the abnormality rate of cabinet No. 1 is 20%, which is less than the preset abnormality rate threshold of 25%, proceed to detailed analysis.

[0130] Calculate the abnormal correlation coefficient for each abnormal mirror (as in the previous example): M is 0.933, X is 0.7, and Y is 0.5.

[0131] Calculate the overall anomaly value (average value) for cabinet No. 1: (0.933+0.7+0.5) / 3 = 0.711.

[0132] 0.711> The preset abnormal threshold is 0.7, so cabinet No. 1 is identified as a problem cabinet. The N disinfected on it is an assessment and analysis target, and the remaining life assessment needs to be initiated.

[0133] Furthermore, the method for determining the updated management strategy for assessing and analyzing the remaining lifespan of the bronchoscope for the aforementioned disease type is as follows: By retrospectively analyzing the assessment results of non-target risk bronchoscopy triggered by target risk bronchoscopy monitoring, the accuracy of the current monitoring mechanism is evaluated. Disease types of frequently misjudged non-target risk bronchoscopy (i.e., those identified as requiring assessment but actually without abnormalities) are upgraded to target risk types, making them part of the monitoring sensor itself. This dynamic adjustment dilutes the proportion of abnormally changing bronchoscopy in each sterilization cabinet, thereby improving the accuracy of subsequent assessments and ultimately avoiding overly frequent assessments of non-target risk bronchoscopy.

[0134] Its core decision-making logic is a hierarchical optimization logic based on the false positive rate. First, it calculates the percentage (abnormal variation ratio) of bronchoscopes with actual abnormal lifespans among all non-target risk bronchoscopes that have undergone additional evaluation. If this ratio is too low, it indicates a large number of false positives, requiring further analysis. Second, it identifies individual bronchoscopes that are frequently subjected to remaining lifespan assessments (affecting bronchoscopes). If the number of these individuals is large, the impact is significant. Therefore, if the lifespan distribution of disease types is highly consistent (high matching coefficient), the entire disease type is upgraded to the target risk type for monitoring. Finally, if the overall false positive rate is moderate, and there are no frequently identified individuals, but the lifespan distribution of certain disease types is highly consistent, a preventative upgrade is implemented. Through this hierarchical optimization, more bronchoscopes with relatively stable lifespan variations are monitored using the target risk type, thereby reducing the impact ratio of abnormal bronchoscopes in each sterilizer and improving monitoring accuracy.

[0135] S41 uses the remaining life assessment results of different bronchoscopes as assessment and analysis targets to determine the proportion of bronchoscopes whose remaining life variation does not meet the requirements, and regards it as the abnormal variation proportion. If the abnormal change ratio is greater than the preset change ratio threshold in the above steps, it indicates that the timeliness of the remaining service life assessment and analysis process by updating the assessment and analysis target is high, so there is no need to update the remaining service life assessment and analysis method.

[0136] It is also understood that if the abnormal change ratio is not greater than the preset change ratio threshold, then proceed to step S42.

[0137] Assessment and analysis targets: These are non-target risk bronchoscopes that, through step S33, are deemed to require an additional remaining life assessment. These bronchoscopes are identified as high-risk due to their use in suspected abnormal sterilization cabinets.

[0138] Bronchoscopes whose remaining lifespan does not meet the requirements: These are bronchoscopes that, after additional high-frequency evaluation, are confirmed to have an abnormal trend such as "a gradual increase in the amount of change in remaining lifespan," and are therefore truly abnormal bronchoscopes.

[0139] Abnormal variation ratio: This refers to the proportion of all non-target risk bronchoscopy lenses listed as assessment targets that are ultimately confirmed to be truly abnormal. This ratio reflects the accuracy of the current monitoring mechanism in identifying non-target risk lenses as requiring assessment. A higher ratio indicates more accurate identification; a lower ratio indicates a large number of false positives, meaning many suspected lenses are actually normal.

[0140] Preset fluctuation ratio threshold: A pre-defined ratio value used to determine if the current monitoring accuracy is high enough. If the abnormal fluctuation ratio is higher than this threshold, it indicates that most of the suspected mirrors are indeed problematic, the monitoring mechanism is effective, and no adjustment is needed. If it is lower than or equal to this threshold, it indicates that there are too many false positives, and optimization is required.

[0141] This step is the starting point of the entire optimization process. Through retrospective analysis of the monitoring results, it quantifies the "false positive rate" of the monitoring mechanism. Only when the false positive rate is high is it necessary to take action to reduce unnecessary assessments, avoid wasting resources, and prevent excessive interference with non-target risk mirrors. If the false positive rate is low, it indicates that the current mechanism is accurate and no changes are needed.

[0142] Suppose that in the past month, the system, through step S33, listed 20 non-targeted high-risk bronchoscopes as assessment targets and initiated more frequent remaining life assessments for them. Subsequent follow-up revealed that only 5 of these bronchoscopes ultimately showed signs of accelerated lifespan decline, while the remaining 15 remained normal. Therefore, the abnormal change rate is 5 / 20 = 25%. If the preset change rate threshold is set to 30%, then 25% < 30%, indicating a high number of misjudgments, requiring further analysis in step S42.

[0143] S42 determines the number of evaluation and analysis processes for the bronchoscope as the evaluation and analysis target based on the evaluation and analysis data; Furthermore, the above steps include the following: S421 uses the number of assessment and analysis processes for bronchoscopes as the assessment and analysis target as the number of correlation processes. It determines whether there are any bronchoscopes with an average daily number of correlation processes greater than the preset correlation process threshold within the most recent preset time period. If so, proceed to step S422. If not, it means that the number of correlation processes for different bronchoscopes is relatively small. Therefore, due to the abnormal fluctuations of the target risk type of bronchoscope, the detection frequency of other bronchoscopes is not high and the impact is not significant. Therefore, there is no need to update the assessment and analysis method for the remaining service life. S422 identifies bronchoscopes with an average daily number of associated processing times exceeding a preset threshold as influencing bronchoscopes. It then determines whether the number of influencing bronchoscopes exceeds a preset threshold. If so, if the maximum value of the lifespan matching coefficient for the disease type in different lifespan intervals exceeds a preset matching coefficient threshold, the remaining lifespan assessment and analysis method for the disease type of bronchoscope is updated to allow each bronchoscope to be disinfected only using a pre-fixed disinfection cabinet, with the goal of maximizing the number of disinfection cabinets used. If not, proceed to step S43. Number of Related Processings: For a given non-target risk bronchoscope, this is the number of times it has been identified as a target for evaluation and analysis by S33 within a recent period (e.g., one month). This number reflects the frequency with which the bronchoscope is "suspected," i.e., the number of times it has been repeatedly misjudged.

[0144] Preset threshold for the number of associated processing times: A pre-set number of times used to determine whether a mirror is suspected too frequently.

[0145] Impact on bronchoscopes: refers to non-target risk bronchoscopes that have an average daily number of associated processing times exceeding a preset threshold, i.e., bronchoscopes that are frequently subjected to repeated remaining life assessments.

[0146] Preset impact threshold: A pre-defined integer used to determine whether the number of frequently identified mirrors is large enough to affect the overall judgment of the disease type.

[0147] Preset matching coefficient threshold: A pre-set coefficient value used to determine whether the life expectancy distribution of a certain disease type is highly concentrated (i.e., the life expectancy of bronchoscopic patients under this disease mostly falls within the same range, with a high matching coefficient). This indicates that the life expectancy pattern of this disease type is very stable and typical.

[0148] The update involves sterilizing each bronchoscope in a pre-installed sterilizer: This upgrades the disease type from a non-target risk type to a target risk type, implementing a "one bronchoscope, one sterilizer" management system, and allocating sterilizers based on maximizing coverage. This means that all bronchoscopes for this disease type will become new monitoring sensors.

[0149] This step aims to identify frequently identified "problem mirrors." If there are many such frequently identified mirrors, it will inevitably lead to unnecessary assessment and analysis of their remaining lifespan, indicating a high level of impact. Upgrading them as target risk types allows these mirrors to take on monitoring tasks themselves, and their normal lifespan fluctuations will be included in the statistics of target risk mirrors, thereby diluting the proportion of abnormal mirrors in each disinfection cabinet and reducing future misjudgments of other non-target risk mirrors.

[0150] After detecting a low abnormal fluctuation ratio in S41, the system counted the number of times each non-target risk bronchoscope was listed as an assessment target in the past month. Three bronchoscopes (denoted as P, Q, and R) were suspected 5, 4, and 3 times respectively, all exceeding the preset monthly average threshold of 3 times. Therefore, they were marked as "affecting bronchoscopes". The system determined that the number of affected bronchoscopes (3) was not greater than the preset threshold for the number of affected bronchoscopes. However, if there were more than 10, the system further queried the lifespan matching coefficient for disease A, finding a maximum value of 0.85, which was greater than the preset matching coefficient threshold of 0.8. Therefore, the system decided to upgrade disease A from a non-target risk type to a target risk type, implementing "one bronchoscope, one cabinet" management for all its bronchoscopes, and allocating them with the goal of covering the most sterilization cabinets.

[0151] S43 is an update management strategy for the assessment and analysis method that determines the remaining lifespan of the bronchoscope for the disease type based on the abnormal variation ratio and the number of assessment and analysis processes using different bronchoscopes as assessment and analysis targets.

[0152] In the above steps, it is determined whether the abnormal change ratio is within the preset change ratio range. If so, as long as the maximum value of the lifespan matching coefficient of the disease type in different lifespan ranges is greater than the preset matching coefficient threshold, and there are no abnormally changing bronchoscopes in the bronchoscopes of the disease type, it is determined that the assessment and analysis method for the remaining lifespan of the bronchoscopes of the disease type will be updated to allow each bronchoscope to be disinfected only using a pre-fixed disinfection cabinet, with the goal of maximizing the number of disinfection cabinets used, and the allocation of disinfection cabinets for the bronchoscopes of the disease type will be carried out. If not, there is no need to update the assessment and analysis method for the remaining lifespan.

[0153] Preset variation ratio range: A pre-defined ratio range (e.g., 10%-20%) is used to define an abnormal variation ratio as being in a "middle state" that is neither too high nor too low. This means that the system may have some misjudgments, but they are not serious, and there are no individuals who are frequently misjudged (because they have been excluded in S42).

[0154] No abnormally variable bronchoscopes: This means that in this disease type, no bronchoscope has been ultimately confirmed as a true abnormally variable bronchoscope. This is a key condition, indicating that the disease type itself is not only stable but also reliable.

[0155] Update process: Similarly, the disease type will be upgraded to the target risk type, and "one mirror, one cabinet" management will be implemented.

[0156] This applies to cases with a moderate false alarm rate and a small number of cases affecting bronchoscopes. If a disease type has a very typical lifespan pattern (high matching coefficient), but overall there are no truly abnormal bronchoscopes and the remaining lifespan is relatively stable, it is necessary to upgrade this disease type to a preventative upgrade by using a lifespan assessment and analysis method specific to the target risk type to further improve the purity of the monitoring network.

[0157] A specific example: Suppose that, according to calculation S41, the overall abnormal variation rate is 15%, which is within the preset variation rate range [10%, 20%]. In S42, any "affecting bronchoscopes" with a daily average number of associated treatments exceeding the threshold is found. At this time, the system scan finds that the maximum lifespan matching coefficient for disease B is 0.88, which is greater than the preset matching coefficient threshold of 0.8, and there are no confirmed truly abnormal bronchoscopes in disease B. All conditions are met, therefore disease B is also upgraded to the target risk type and "one bronchoscope, one cabinet" management is implemented.

[0158] Example 3 Thirdly, this application provides a chip for the aforementioned multi-source data fusion-based bronchoscope end-to-end management system, characterized in that it specifically includes: The data acquisition interface is configured to acquire usage data of the bronchoscope, and the storage unit is configured to store preset threshold parameters and program instructions.

[0159] The various embodiments in this specification are described in a progressive manner. Similar or identical parts between embodiments can be referred to mutually. Each embodiment focuses on describing the differences from other embodiments. In particular, the embodiments of apparatus, devices, and non-volatile computer storage media are basically similar to the method embodiments, so the descriptions are relatively simple; relevant parts can be referred to the descriptions of the method embodiments.

[0160] The foregoing has described specific embodiments of this specification. Other embodiments are within the scope of the appended claims. In some cases, the actions or steps recited in the claims may be performed in a different order than that shown in the embodiments and may still achieve the desired result. Furthermore, the processes depicted in the drawings do not necessarily require the specific or sequential order shown to achieve the desired result. In some embodiments, multitasking and parallel processing are possible or may be advantageous.

[0161] The above description is merely one or more embodiments of this specification and is not intended to limit this specification. Various modifications and variations can be made to the one or more embodiments of this specification by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principle of one or more embodiments of this specification should be included within the scope of the claims of this specification.

Claims

1. A multi-source data fusion management system for the entire process of bronchoscope operation, characterized in that, Specifically, it includes: The system includes a clinical diagnosis and treatment module, a processing module, a linkage module, and a central monitoring module. The clinical diagnosis and treatment module is responsible for linking patient information, registering the use records of the bronchoscope, and registering the post-use status. The processing module is responsible for receiving and confirming the entire process record of the bronchoscope, automatically collecting cleaning parameters, and using the fluctuation of the bronchoscope's lifespan in different disease types to determine the assessment and analysis method for the remaining lifespan of the bronchoscope in the disease type. Based on the usage data of the bronchoscope for the target risk type and the assessment risk type of different disease types, the module determines the disinfection management strategy for the target risk type. Based on the assessment and analysis results of the remaining lifespan of different bronchoscopes and the assessment and analysis processing data, the module determines the updated management strategy for the assessment and analysis method of the remaining lifespan of the bronchoscope for the disease type. The linkage module is responsible for receiving microbial monitoring applications, reporting monitoring results, and automatically triggering early warning and recall processes. The central monitoring module is responsible for displaying the status of all bronchoscopes in real time, graphically displaying the complete flow path of the bronchoscopes and all operation records, and generating various reports.

2. The multi-source data fusion-based bronchoscope end-process management system as described in claim 1, characterized in that, The complete process record of the bronchoscope includes leak detection, cleaning, disinfection, drying, and storage.

3. The multi-source data fusion-based bronchoscope end-process management system as described in claim 1, characterized in that, The reports include workload, pass rate, early warning rate, and consumable usage.

4. A multi-source data fusion-based full-process management method for bronchoscopes, applied to the multi-source data fusion-based full-process management system for bronchoscopes as described in any one of claims 1-3, characterized in that, Specifically, it includes: Based on the usage data of bronchoscopes, the fluctuation of the lifespan of bronchoscopes in different disease types is determined. Based on the fluctuation, an assessment and analysis method for the remaining lifespan of the bronchoscope in the disease type is determined. The assessment and analysis method is used to determine the assessment risk type for different disease types. Based on the usage data of bronchoscopes of the target risk type and in combination with the assessment risk type for different disease types, the disinfection management strategy for the target risk type is determined. Based on the assessment and analysis results of the remaining lifespan of bronchoscopes of different target risk types in different disinfection cabinets, bronchoscopes whose remaining lifespan variation does not meet the requirements are identified. Combined with the assessment and analysis results of the remaining lifespan of bronchoscopes whose remaining lifespan variation does not meet the requirements in other disinfection cabinets, the target for assessment and analysis of the remaining lifespan of bronchoscopes is determined. Based on the assessment and analysis results of the remaining lifespan when using different bronchoscopes as the assessment and analysis targets, and the assessment and analysis processing data, the updated management strategy for the assessment and analysis method of the remaining lifespan of bronchoscopes for the aforementioned disease types is determined.

5. The multi-source data fusion-based full-process management method for bronchoscopes as described in claim 4, characterized in that, The data on the use of the bronchoscope includes the number of times it is used in different disease types and its lifespan.

6. The multi-source data fusion-based full-process management method for bronchoscopes as described in claim 4, characterized in that, The fluctuation in the lifespan of the bronchoscope in different disease types is determined based on the lifespan range of the bronchoscope in each disease type.

7. The multi-source data fusion-based full-process management method for bronchoscopes as described in claim 4, characterized in that, The method for determining the assessment and analysis of the remaining lifespan of the bronchoscope in the disease type is as follows: S11 determines the lifespan range of the bronchoscope in the disease type based on the fluctuation situation; S12 determines the lifespan matching coefficient for the service life range by the proportion of the number of bronchoscopes in different service life ranges. S13 is an assessment and analysis method for determining the remaining lifespan of the bronchoscope in a given disease type based on the lifespan matching coefficient of different disease types in different lifespan ranges.

8. The method for full-process management of bronchoscope using multi-source data fusion as described in claim 7, characterized in that, An assessment and analysis method for determining the remaining lifespan of the bronchoscope in a given disease type is based on lifespan matching coefficients for different disease types within different lifespan ranges. This method specifically includes: Based on the maximum value of the lifespan matching coefficient in different lifespan ranges, the lifespan fluctuation coefficient of the disease type is determined. If the lifespan fluctuation coefficient of the disease type is greater than the preset fluctuation coefficient threshold, then the remaining lifespan of the bronchoscope in the disease type is determined to be evaluated and analyzed according to the baseline number of uses.

9. The method for full-process management of fiberoptic bronchoscope using multi-source data fusion as described in claim 1, characterized in that, The method for determining the updated management strategy for assessing and analyzing the remaining lifespan of bronchoscopy for the aforementioned disease types is as follows: The remaining lifespan of different bronchoscopes is evaluated and analyzed to determine the proportion of bronchoscopes whose remaining lifespan does not meet the requirements, and this proportion is identified as the abnormal variation proportion. Based on the evaluation and analysis data, determine the number of evaluation and analysis processes to be performed on the bronchoscope as the evaluation and analysis target; Based on the abnormal variation ratio and the number of assessment and analysis processes using different bronchoscopes as assessment and analysis targets, an update management strategy is developed for the assessment and analysis method to determine the remaining lifespan of the bronchoscope for the disease type.

10. A chip for use in a multi-source data fusion bronchoscopy end-process management system as described in any one of claims 1-3, characterized in that, Specifically, it includes: The data acquisition interface is configured to acquire usage data of the bronchoscope, and the storage unit is configured to store preset threshold parameters and program instructions.

Images